Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201

Rachel Grisham; Els Van Nieuwenhuysen; Alessandro Santin; Véronique D'Hondt; Premal Thaker; Andrew Clamp; Kathleen Moore; Carol Aghajanian; Alejandro Perez-Fidalgo; David O'Malley; Bradley Monk; et al.

doi:10.1016/j.ygyno.2026.01.052

Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201

Rachel Grisham, Els Van Nieuwenhuysen, Alessandro Santin, Véronique D'Hondt, Premal Thaker, Andrew Clamp, Kathleen Moore, Carol Aghajanian, Alejandro Perez-Fidalgo, David O'Malley, …

Gynecologic oncology, Vol.208, pp.S30-S31

05/2026

: https://doi.org/10.1016/j.ygyno.2026.01.052

1

: Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
: Rachel Grisham - Memorial Sloan Kettering Cancer Center
Els Van Nieuwenhuysen - University Hospitals Leuven, Leuven Cancer Institute, BGOG, Leuven, Belgium
Alessandro Santin - Yale School of Medicine
Véronique D'Hondt - Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine, Oncologie Médicale, GINECO, Montpellier, France
Premal Thaker - Division of Gynecologic Oncology, Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO, United States
Andrew Clamp - University of Manchester
Kathleen Moore - University of Oklahoma Health Sciences Center
Carol Aghajanian - Memorial Sloan Kettering Cancer Center
Alejandro Perez-Fidalgo - Hospital Clínico Universitario de Valencia
David O'Malley - The Ohio State University
Bradley Monk - Florida Cancer Specialists, West Palm Beach, FL, United States
et al.
: Gynecologic oncology, Vol.208, pp.S30-S31
: Elsevier Inc
: 991006271509702656
: Obstetrics & Gynecology
: English
: Journal article